Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | MicrobiomeTrials
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-16Est. Completion: 2030-12-01
Enrollment target: 32 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States